Kyntra Bio, Inc. (KYNB)
| Market Cap | 7.41M -78.9% |
| Revenue (ttm) | 5.30M -36.1% |
| Net Income | -17.29M |
| EPS | -4.27 |
| Shares Out | 4.05M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,673 |
| Open | 1.950 |
| Previous Close | 1.950 |
| Day's Range | 1.780 - 1.950 |
| 52-Week Range | 1.780 - 10.470 |
| Beta | 1.11 |
| Analysts | Buy |
| Price Target | 22.75 (+1,143.17%) |
| Earnings Date | Nov 16, 2026 |
About KYNB
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for KYNB stock is "Buy." The 12-month stock price target is $22.75, which is an increase of 1,143.17% from the latest price.
News
Kyntra Bio price target lowered to $8 from $41 at Lake Street
Lake Street lowered the firm’s price target on Kyntra Bio (KYNB) to $8 from $41 and keeps a Buy rating on the shares. Kyntra said that based on an interim…
Kyntra Bio price target lowered to $30 from $35 at Oppenheimer
Oppenheimer lowered the firm’s price target on Kyntra Bio (KYNB) to $30 from $35 and keeps an Outperform rating on the shares. The firm is encouraged by Kyntra’s decisive pivot…
Kyntra Bio price target lowered to $18 from $43 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Kyntra Bio (KYNB) to $18 from $43 and keeps a Buy rating on the shares. A planned interim analysis of the company’s…
Kyntra Bio Earnings Call Transcript: Q3 2026
FG-3246/FG-3180 development ended, redirecting resources to roxadustat Phase III, targeted for Q1 2027 pending financing. Q3 net income included a $14M restructuring gain; cash and receivables totaled $44.1M.
Kyntra Bio Earnings release: Q3 2026
Kyntra Bio released its Q3 2026 earnings on November 16, 2026, summarizing the period's financial results.
Kyntra Bio Quarterly report: Q3 2026
Kyntra Bio has published its Q3 2026 quarterly earnings report on November 16, 2026.
Kyntra Bio reports Q3 EPS 4c vs. ($3.25) last year
Reports Q3 revenue $1.76M, consensus $1.72M. “Following a pre-planned interim analysis showing insufficient efficacy, we have made the decision to terminate the FG-3246 Phase 2 trial,” said Thane Wett...
Kyntra Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Completed restructuring of royalty financing agreement, reducing the maximum aggregate payment obligation by $60 million, with only $15 million in future royalty-backed payments remaining Initiation o...
Kyntra Bio Slides: Corporate presentation
Kyntra Bio has posted slides in relation to its latest quarterly earnings report, which was published on November 16, 2026.
Kyntra Bio to Report Third Quarter 2026 Financial Results
SAN FRANCISCO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also cond...
Kyntra Bio initiated with a Buy at Maxim on mCRPC potential
As previously reported, Maxim initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $35 price target Kyntra has “traversed a challenging period since its FibroGen days,” refining its…
Kyntra Bio initiated with a Buy at Maxim
Maxim analyst Michael Okunewitch initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $35 price target
Kyntra Bio appoints Singer to its board of directors
Kyntra Bio (KYNB) announced the appointment of Andrew Singer, MBA to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. The…
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
SAN FRANCISCO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the appointment of Andrew E. Singer, MBA to its Board of Directors as an independent director and member of t...
Kyntra Bio initiated with a Buy at Lake Street on prostate cancer potential
As previously reported, Lake Street analyst Daniel Brims initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $41 price target Kyntra is developing drugs for solid and hematological…
Kyntra Bio initiated with a Buy at Lake Street
Lake Street initiated coverage of Kyntra Bio (KYNB) with a Buy rating and $41 price target
Kyntra Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Kyntra Bio, rebranded from FibroGen, is advancing two key programs: a phase II trial for FG-3246 in mCRPC with interim results expected Q4 2024, and a phase III trial for roxadustat in lower risk MDS, also set to begin Q4 2024. Both programs target significant unmet needs and large markets.
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company's management will be attending and presenting at the H.C. Wainwright 28th Annual Global Inv...
Kyntra Bio cuts max royalty cap to $65M from $125M, pays $42.6M upfront
Kyntra Bio (KYNB) announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoebus, materially reducing its payment obligations under the agree...
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced the signing of an amendment and restatement of its existing royalty financing agreement with NQ Project Phoeb...
Kyntra Bio reports Q2 EPS $2.96, consensus ($3.18)
“We continue to make progress across our oncology and rare disease portfolio and remain laser-focused on advancing toward our goal of initiating a pivotal Phase 3 trial of roxadustat in…
Kyntra Bio Earnings Call Transcript: Q2 2026
Clinical programs for FG-3246 in mCRPC and roxadustat in lower risk MDS advanced, with key trials on track and strong cash reserves supporting operations into 2028. Q2 2026 saw a return to net income and increased R&D investment.
Kyntra Bio Earnings release: Q2 2026
Kyntra Bio released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Kyntra Bio Quarterly report: Q2 2026
Kyntra Bio has published its Q2 2026 quarterly earnings report on August 13, 2026.
Kyntra Bio Slides: Q2 2026
Kyntra Bio has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.